Project Number 5R01AG018440-15 Agency/Funding Organization NIA Funding Year 2015 View Full Project Details for A-SYNUCLEIN CLEARANCE STRATEGIES FOR THE TREATMENT OF LEWY BODY DISEASE Research Categorization Primary Disease / Condition Lewy Body Dementias CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 5. Other Proteinopathies a. Alpha-Synuclein Researcher and Organization Principal Investigator RISSMAN, ROBERT A Principal Investigator First Name ROBERT Principal Investigator Last Name RISSMAN Awardee Organization UNIVERSITY OF CALIFORNIA SAN DIEGO Awardee State California Contact PI Country United States Project Detail FY Overall Cost $275,621 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official REFOLO, LORENZO Related Resources Repository [AlzPED] Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease [AlzPED] Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease. [AlzPED] Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. [AlzPED] Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease. [AlzPED] Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. [AlzPED] Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. Patent Compounds for reversing and inhibiting protein aggregation| and methods for making and using them Transgenic mouse model for neurodegenerative diseases
